



N 10/044,896

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	CHUNTHARAPAI ET AL.	Examiner:	Y. KIM
Serial No.:	10/044,896	Group Art Unit:	1644
Filed:	JANUARY 9, 2002	Docket No.:	11669.147USU1
Confirmation No.:	1225	Customer No.:	23552
Title:	ANTI-INTERFERON-ALPHA ANTIBODIES		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 371503640 US
Date of Deposit: April 1, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: 
Name: Sheryl A. Boefboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

04/06/2005 BABRAHA1 00000073 10044896

01 FC:1806

180.00 0P

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: _____

April 1, 2005


Katherine M. Kowalchuk
Reg. No. 36,848
KMK:sab



FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1

Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,289,690	09-15-1981	Pestka			
	4,341,761	07-27-1982	Ganfield			
	4,423,147	12-27-1983	Secher			
	4,474,754	10-02-1984	Shimizu			
	4,514,507	04-30-1985	Secher			
	4,824,432	04-25-1989	Skurkovich			
	4,973,556	11-27-1990	Bove			
	5,055,289	10-08-1991	Frincke			
	5,073,491	12-17-1991	Familletti			
	5,196,323	03-23-1993	Bodo			
	5,240,864	08-31-1993	Koga			
	5,317,089	05-31-1994	Adolf			
	5,503,828	04-02-1996	Testa			
	5,516,515	05-14-1996	Vellucci			
	5,626,843	05-06-1997	Skurkovich			
	5,676,942	10-14-1997	Testa			
	5,780,027	07-14-1998	Maroun			
	5,789,551	08-04-1998	Pestka			
	5,869,293	02-09-1999	Pestka			
	5,888,511	03-30-1999	Skurkovich			
	5,919,453	07-06-1999	Benoit			
	6,001,589	12-14-1999	Pestka			
	6,117,423	09-12-2000	Berg			
	6,136,309	10-24-2000	Novick			
	6,150,503	11-21-2000	Pestka			
	2001/0012514	08-09-2001	Skurkovich			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1


Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644



	6,299,870	10-09-2001	Pestka			
	6,300,474	10-09-2001	Pestka			
	6,312,924	11-06-2001	Presnell			
	6,333,032	12-25-2001	Skurkovich			
	6,410,697	06-25-2002	Berg			
	6,433,145	08-13-2002	Lafleur			
	2002/0192748	12-19-2002	Rastelli			
	6,514,753	02-04-2003	Pestka			
	2003/0044410	03-06-2003	Skurkovich			
	6,548,056	04-15-2003	Presnell			
	2003/0138404	07-24-2003	Maroun			
	2003/0147581	08-07-2003	Doi			
	2003/0147889	08-07-2003	Tovey			
	2004/0067888	04-08-2004	Tovey			
	2004/0105841	06-03-2004	Pestka			
	6,747,131	06-08-2004	Pestka			
	2004/0110715	06-10-2004	Escary			
	2004/0126799	07-01-2004	Escary			
	2004/0132139	07-08-2004	Escary			
	2004/0142431	07-22-2004	Escary			
	2004/0203118	10-14-2004	Escary			
	6,827,934	12-07-2004	Co et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	CA 1306961	9-1-92	Canada				
	DD 231007	12-18-85	East Germany			Abstract Only	
	DD 254593	3-2-88	East Germany			Abstract Only	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1

Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644



	DD 265291	3-1-89	East Germany			Abstract Only	
	DD 277087	3-21-90	East Germany			Abstract Only	
	DD 279266	5-30-90	East Germany			Abstract Only	
	DD 279317	5-30-90	East Germany			Abstract Only	
	DD 279546	6-6-90	East Germany			Abstract Only	
	DD 279547	6-6-90	East Germany			Abstract Only	
	DD 279548	6-6-90	East Germany			Abstract Only	
	DD 283154	10-3-90	East Germany			Abstract Only	
	EP 0 050 129	3-18-92	Europe				
	EP 0 064 063	9-11-85	Europe				
	EP 0 091 543	10-19-83	Europe				
	EP 0 119 476	2-16-84	Europe			Abstract Only	
	EP 0 158 420	11-7-90	Europe				
	EP 0 332 084		Europe				
	EP 0 431 950	6-12-91	Europe				
	EP 1 236 800	9-4-02	Europe				
	FR 2657881	8-9-91	France			Abstract Only	
	DE 4216200	11-18-93	Germany			Abstract Only	
	GB 2111527	7-6-83	United Kingdom				
	GB 2160544	12-24-85	United Kingdom				
	JP 4077431	3-11-92	Japan			Abstract Only	
	JP 58035122	3-1-83	Japan			Abstract Only	
	JP 58035124	3-1-83	Japan			Abstract Only	
	JP 58225028	12-27-83	Japan			Abstract Only	
	JP 60065000	4-13-85	Japan			Abstract Only	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1

Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644



	JP 60065000	4-13-85	Japan			Abstract Only	
	JP 6050971	2-25-94	Japan			Abstract Only	
	JP 61072722	4-14-86	Japan			Abstract Only	
	JP 61099828	5-17-86	Japan			Abstract Only	
	JP 61225136	10-6-86	Japan			Abstract Only	
	JP 63142000	6-14-88	Japan			Abstract Only	
	KR 8801757	9-12-88	Korea			Abstract Only	
	KR 9200051	1-6-92	Korea			Abstract Only	
	SU 1756349	8-23-92	Soviet Union			Abstract Only	
	WO 82/01773	5-27-82	PCT				
	WO 83/00693	3-3-83	PCT				
	WO 93/20187	10-14-93	PCT				
	WO 95/13539	5-18-95	PCT			Abstract Only	
	WO 98/06431	2-19-98	PCT				
	WO 98/28001	7-2-98	PCT				
	WO 99/64440	12-16-99	PCT				
	WO 00/32223	6-8-00	PCT				
	WO 01/54721	8-2-01	PCT				
	WO 01/62287	8-30-01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	On Line Catalog Data Sheet for Anti-Interferon Alpha Antibodies available from Research Diagnostics, Rev. March 8, 2001, http://www.researchd.com/cytokines/ifnachrt.htm (Printed February 10, 2004)
	Antalis et al. 1998. The serine protease inhibitor (Serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon α/β priming. <i>J. Exp. Med.</i> 187: 1799-1811.
	Blanco et al. 2001. Induction of dendritic cell differentiation by IFN- α in systemic lupus erythematosus. <i>Science</i> . 294: 1540-1543.
	Cai & Garen, 1996. A melanoma-specific V _H antibody cloned from a fusion phage library of a vaccinated melanoma patient. <i>Proc. Natl. Acad. Sci. USA</i> . 93: 6280-6285.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1

Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Colamonici et al. 1993. Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. <i>J. Biol. Chem.</i> 268: 10895-10899.
	Dansky-Ullmann et al. 1995. Synergistic effects of IL-6 and IFN- γ on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN- β . <i>Cytokine</i> . 7: 118-129.
	Desmyter et al. 2002. Three camelid VHH domains in complex with porcine pancreatic α -amylase. <i>J. Biol. Chem.</i> 277: 23645-23650.
	Dhib-Jalbut et al. 1993. Direct evidence that interferon- β mediates enhanced HLA-class I expression in measles virus-infected cells. <i>J. Immunol.</i> 151: 6248-6252.
	Edge et al. 1983. Chemical synthesis of a human interferon- α_2 gene and its expression in <i>escherichia coli</i> . <i>Nucleic Acids Res.</i> 11: 6419-6435.
	Kobiler et al., "Production of Monoclonal Antibodies Toward Bovine Interferons- α Suitable for Immunopurification", <i>J. Interferon Res.</i> , 9(2):189-193 (1989).
	Liu et al., "High-Yield Expression and Purification of Human Interferon α -1 in <i>Pichia pastoris</i> ", <i>Protein Exp. Purif.</i> , 22(3):381-387 (2001).
	Meager et al., "Development of Interferon-Specific Monoclonal Antibody for <i>In Vitro</i> Interferon Assays", <i>Dev. Biol. Stand.</i> , 64:237-248 (1986).
	Noraz et al. 1997. Human cytomegalovirus-associated immunosuppression is mediated through interferon- α . <i>Blood</i> . 89: 2443-2452.
	Slocombe et al. 1982. High-level expression of an interferon α_2 gene cloned in phage M13mp7 and subsequent purification with a monoclonal antibody. <i>Proc. Natl. Acad. Sci. USA</i> . 79: 5455-5459.
	Staehelin et al. 1981. Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. <i>J. Biol. Chem.</i> 256: 9750-9754.
	Subauste et al. 1998. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. <i>J. Immunol.</i> 160: 1831-1840.
	Taylor-Papadimitriou, "Epitopes of Human Interferon- α Defined by the Reaction of Monoclonal Antibodies with α Interferons and Interferon Analogues", <i>J. Immunol.</i> , 139(10):3375-3381 (1987).
	Vaughan et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", <i>Nature Biotechnology</i> , 14:309- (1996)
	Veenstra et al. 2002. IL-12 induces monocyte IL-18 binding protein expression via IFN- γ . <i>J. Immunol.</i> 168: 2282-2287.
	Viscomi et al. 1999. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN- α by monoclonal antibodies. <i>J. Interferon Cytokine Res.</i> 19: 319-326.
	Zella et al. 2000. IFN- α_2b reduces IL-2 production and IL-2 receptor function in primary CD4 ⁺ T cells. <i>J. Immunol.</i> 164: 2296-2302.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.147USU1

Application Number:

10/044,896

Applicant: Chuntharapai et al.

Filing Date: January 9, 2002

Group Art Unit: 1644

Zoon et al. 1992. Purification and characterization of multiple components of human lymphoblatoid Intereron- α
J. Biol. Chem. 267: 15210-15216.

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.